DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate.

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Critical Metals, Rare Earths and the Western Supply Chain Race: From CRML’s Tanbreez Update to the Mine-to-Magnet Economy

Critical Metals Corp. ($CRML) is the starting point, but the full map reaches across MP Materials ($MP), USA Rare Earth ($USAR), Energy Fuels ($UUUU), NioCorp ($NB), Lithium Americas ($LAC), Albemarle ($ALB), Sigma Lithium ($SGML), Nouveau Monde Graphite ($NMG) and Westwater Resources ($WWR): heavy rare earths, lithium, graphite, niobium, scandium, magnet manufacturing, defense procurement, EV motors, wind turbines, robotics, electronics and the geopolitical race to rebuild strategic supply chains outside China.
Insider Trading This Week: The 20 Biggest Buys and Sells

Insider trading this week (June 29-July 3, 2026): the 20 biggest buys and 20 biggest sells by dollar value, with names, tickers, amounts and next catalysts.
AI: the 10 hottest stocks of July 2026

Ten artificial-intelligence names, screened for momentum, chart position and base, with the genuine small/mid caps up top. For each one: a mini chart, a short explainer, the AI niche and the real analyst price targets with sources.
Defense: the 10 hottest stocks of July 2026

Watchlist 2026 · Defense & Defense-Tech Drones Space Counter-UAS Momentum AVAV · KTOS · RKLB · LUNR · PL · DRS · KRMN · RCAT · UMAC · ONDS Defense: the 10 hottest stocks of July 2026 Ten small and…
Atlas Lithium ($ATLX) Deep Dive 2026

The junior developer aiming to bring the Neves hard-rock lithium project into production in Minas Gerais' "Lithium Valley": a fully paid processing plant already shipped to Brazil, offtake deals with Mitsui, Chengxin and Yahua — but also years of delays, heavy dilution and a CEO who controls 51% of the vote.
NANO Nuclear Energy ($NNE) Deep Dive 2026

The microreactor developer aiming to become a fully integrated nuclear supply chain for the AI data-center era: pre-commercial technology, a large cash pile and a calendar of regulatory and test milestones.
$MVIS MicroVision: Small-Cap LiDAR Reawakens as Defense, Security and AI Robotics Become the New Battleground

MicroVision’s new Southeast Asia partnership adds another piece to a busy 2026 commercial reset, but the story remains a high-risk execution trade: stronger customer activity, broader LiDAR portfolio, still-small revenue, meaningful cash burn and visible financing risk.
Biotech Radar July 1, 2026: $CANF, $ABVX, $SXTP and $MODD Lead Today’s Catalyst Watch

Today’s biotech tape is not built around one single mega-cap headline. It is a classic catalyst radar session: one small oncology name with a fresh Phase 2a survival signal, one late-stage inflammatory disease story with a major Phase 3/NDA setup but financing pressure, one infectious-disease micro-cap tied to babesiosis development, and one diabetes medtech name moving from clearance into real-world use.
Abivax (NASDAQ: $ABVX): Obefazimod, the ABTECT Phase 3 Safety Reset and the Q4 2026 NDA Path

Abivax has moved from a speculative French biotech story to one of the most closely watched late-stage ulcerative colitis names in global healthcare. The June 29 ABTECT Maintenance Part 2 update did not simply add another dataset. It directly addressed the safety debate that had pressured the stock after the June 1 maintenance readout and pushed investors to reassess the risk/reward profile ahead of the planned U.S. NDA submission in Q4 2026.
VisionWave Holdings (Nasdaq: $VWAV): Meteor Aerospace Deal

Deep Dive · Defense Autonomy · $VWAV VisionWave Holdings (Nasdaq: $VWAV): Meteor Aerospace Deal Turns the Pre-Market Spike Into a Real Defense-Autonomy Test VisionWave announced a definitive binding agreement to acquire a 51% controlling interest in Meteor Aerospace, an Israeli…
DEA Cannabis Hearing Begins: Why Schedule III Still Matters for $TLRY, $CGC and $MSOS

The market did not get a final ruling today. What it got is the start of a federal process that could decide whether the cannabis trade remains a narrow medical-only tax story or becomes a broader sector repricing catalyst.
Analyst Price Targets in Biotech: Why the Most Quoted Number Is Often the Least Useful One

A deeper, U.S.-focused Merlintrader editorial on how to read sell-side price targets in small and mid-cap biotech, why 12-month targets often fail as forecasts, and why binary events such as PDUFA dates, Phase 3 readouts and FDA advisory committees can turn the “average target” into a misleading comfort number.
Three Space Stories That Matter Now: $RKLB’s Iridium Shock, $ASTS’s August Launch Window, and Rocket Lab’s NASA Credibility Trade. $IRDM

The public space sector just received a concentrated set of catalysts: Rocket Lab is trying to buy an operating satellite communications network, AST SpaceMobile has placed its next BlueBird batch on the launch calendar, and NASA has selected Rocket Lab for dedicated Sun/Earth science missions. Together, these updates show how the investable space trade is moving beyond launch hype and into infrastructure, networks, services, and execution.
Three Biotech Stories That Matter Now: Ipsen-Kartos M&A, $CAPR’s FDA AdCom, and $REPL’s RP1 Resubmission

The biotech calendar is entering a dense FDA-driven window, with three Nasdaq-listed names standing out for very different reasons: a renal-disease PDUFA decision watch, a rare-disease cell therapy advisory committee, and an oncology BLA resubmission that has put accelerated approval back in focus.
Space Economy 2026: $ASTS vs $RKLB vs $SPCE vs $FJET — Four Business Models Compared

Space Economy · $ASTS · $RKLB · $SPCE · $FJET Space Economy 2026: $ASTS vs $RKLB vs $SPCE vs $FJET — Four Business Models Compared A focused comparison of four publicly traded US space-economy names: satellite-to-phone connectivity ($ASTS), launch and…
Russell 2026 Final Rebalance Radar: Best Post-Upgrade Stocks to Watch by Sector

A sector-by-sector operational screen of the June 2026 Russell reconstitution, focused on stocks that deserve attention after the index event because chart structure, post-rebalance volume, fundamentals, catalysts and analyst target references overlap.
Space Stocks Selloff: Why $PL, $LUNR, $SATL, $ASTS and RKLB Are Falling Together After June’s Rally

The June space trade is no longer being priced stock by stock. Planet Labs, Intuitive Machines, Satellogic, AST SpaceMobile and Rocket Lab are being traded as one high-beta space basket — and the unwind has exposed the same pressure points across the sector: SpaceX gravity, ETF outflows, valuation resets, execution risk, launch cadence, defense-contract timing and profit-taking after a crowded rally.
Russell 2026 Biotech Watchlist: $UNCY, $GALT, $SPRB, $OVID and the Small-Cap Health Care Additions to Watch

RUSSELL 2026 PRELIMINARY LIST 87 HEALTH CARE ADDITIONS BIOTECH FOCUS Russell 2026 Biotech Watchlist: $UNCY, $GALT, $SPRB, $OVID and the Small-Cap Health Care Additions to Watch The June 2026 Russell reconstitution becomes effective after the U.S. market close on June…
4 FDA PDUFA Dates — Week of June 29–30, 2026

ARQT, LNTH and UNCY face FDA target action dates on June 29, while VRDN follows on June 30. The setup spans pediatric dermatology, nuclear medicine imaging, dialysis-related nephrology and thyroid eye disease — four very different regulatory events with very different trading profiles.
Report date: June 25, 2026
Financial data: latest Q1 2026 updates where available
$PLSM $ICCM $SLN: Remote Care, Cryoablation and siRNA Catalysts Move Back Into Focus

Three healthcare small caps enter the morning radar for different reasons: Pulsenmore is pushing FDA-authorized home ultrasound into U.S. virtual maternity care, IceCure is building the clinical-validation story around ProSense cryoablation, and Silence Therapeutics is moving closer to a Phase 2 SANRECO readout for divesiran in polycythemia vera.


